NJ State Employees Deferred Compensation Plan Has $107,000 Stake in ArQule, Inc. (ARQL)
NJ State Employees Deferred Compensation Plan held its position in ArQule, Inc. (NASDAQ:ARQL) during the second quarter, Holdings Channel reports. The fund owned 86,202 shares of the biotechnology company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in ArQule were worth $107,000 at the end of the most recent quarter.
Separately, Renaissance Technologies LLC raised its position in ArQule by 1.4% in the fourth quarter. Renaissance Technologies LLC now owns 2,017,600 shares of the biotechnology company’s stock valued at $2,542,000 after buying an additional 26,900 shares during the last quarter. 60.41% of the stock is owned by hedge funds and other institutional investors.
ArQule, Inc. (NASDAQ ARQL) opened at 1.00 on Friday. ArQule, Inc. has a 52-week low of $0.92 and a 52-week high of $1.82. The company’s 50-day moving average price is $1.21 and its 200 day moving average price is $1.19. The firm’s market capitalization is $71.15 million.
ArQule (NASDAQ:ARQL) last posted its earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same quarter last year, the firm earned ($0.07) EPS. Equities analysts predict that ArQule, Inc. will post ($0.43) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/11/nj-state-employees-deferred-compensation-plan-has-107000-stake-in-arqule-inc-arql.html.
Separately, Zacks Investment Research lowered ArQule from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Want to see what other hedge funds are holding ARQL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ArQule, Inc. (NASDAQ:ARQL).
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.